Last reviewed · How we verify
5 mg
At a glance
| Generic name | 5 mg |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Edema
- Fatigue
- Nausea
- Abdominal pain
- Somnolence
Serious adverse events
- Angioedema
- Arrhythmia (including ventricular tachycardia and atrial fibrillation)
- Syncope
- Pancreatitis
- Erythema multiforme
- Thrombocytopenia
- Leukopenia
- Dysphagia
- Vasculitis
- Allergic reaction
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment (NA)
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5 mg CI brief — competitive landscape report
- 5 mg updates RSS · CI watch RSS
- Pfizer portfolio CI